CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1987
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
7158
Agency Tracking Number:
7158
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
410 West Harrison Street, Seattle, WA, 98119
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
GOWSALA PAVANASASIVAM PHD
(206) 281-7001
Business Contact:
() -
Research Institute:
n/a
Abstract
NEORX CORPORATION PROPOSES A NEW SERIES OF SMALL-MOLECULAR WEIGHT NATURAL PRODUCTS THAT ARE SIMILAR TO HIGHER PLANT TOXINS IN THEIR MECHANISMS OF ACTION-INHIBITING PROTEIN SYNTHESIS AT THE LEVEL OF THE RIBOSOME. ALL INHIBIT IN VIVOTRANSLATION IN CELL-FREE SYSTEMS. SOME ARE CYTOTOXIC TO EUCARYOTIC CELLS AT LOW CONCENTRATIONS (ID50 100PG/ML) AND THUS BEHAVE LIKE THE "INTACT" DIMERIC TOXINS RICIN AND ABRIN; OTHERS ARE NOT CYTOTOXIC AT RELATIVELY HIGH CONCENTRATIONS (10 /ML) AND ARE SIMILAR TO RIBOSOMAL INACTIVATING PROTEINS (RIPS) SUCH AS GELONIN. MONOCLONAL ANTIBODIES (MOARBS) ARE PROPOSED AS VEHICLES TO FACILITATE BINDING AND INTERNALIZATION OF THE NONCYTOTOXIC (RIP-LIKE) MOLECULES AND TO ENHANCE SELECTIVITY OF THE CYTOTOXIC (INTACT TOXIN-LIKE) MOLECULES. TWO OF THE RIP-LIKE MOLECULES, DIFFERING ONLY IN ONE SITE OFACETYLATION, AND ONE TOXIN-LIKE MOLECULE TO AN ANTIMELANOMA MOAB WILL BE CONJUGATED AND TESTED FOR INHIBITION OF PROTEINSYNTHESIS AND OVERALL CYTOTOXICITY AND SELECTIVITY WITH ANTIGEN-POSITIVE AND ANTIGEN-NEGATIVE MELANOMA CELLS. THEIRCONJUGATES MAY HAVE EQUIVALENT POTENCY BUT NOT SUFFER THE POOR DELIVERY CAUSED BY NONSPECIFIC UPTAKE AS OCCURS WITH HIGHER MOLECULAR WEIGHT TOXINS. THEY ARE ALSO NOT LIKELY TOSUFFER FROM DRUG-INDUCED CROSS-RESISTANCE, AS OCCURS WITH DRUGS CURRENTLY USED IN CHEMOTHERAPY. SHOULD EITHER OR BOTHOF THESE APPROACHES PROVE FEASIBLE, IT WILL BE POSSIBLE TO CONSTRUCT SEVERAL GENERATIONS OF A WIDE RANGE OF RELATED ANTITUMOR AGENTS THAT HAVE UNIQUE MECHANISMS OF ACTION AND THAT WILL BE IMPORTANT NEW AGENTS FOR THE TREATMENT OF CANCER.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government